An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2016
At a glance
- Drugs Romiplostim (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Amgen
- 14 Apr 2016 This trial was completed in Spain,Hungary, Austria, Slovakia, Poland (end date: 2011-06-28), Czech Republic (end date: 2011-09-28), Denmark, Germany (end date: 2011-02-23), Belgium (end date: 2011-07-18), and in Netherlands according to European Clinical Trials Database record.
- 21 Apr 2012 Planned end date changed from 23 Feb 2011 to 23 Feb 2012 as reported by European Clinical Trials Database record.
- 24 Mar 2012 Planned end date changed from 5 Jun 2011 to 23 Feb 2011 as reported by European Clinical Trials Database.